破裂性腹主动脉瘤腔内修复术后Ⅱ型内漏的国际多中心早期与晚期结局比较
该研究纳入德国、意大利和瑞士三家三级转诊中心2018年1月至2022年12月因破裂性腹主动脉瘤行EVAR的123例患者,按有无早期Ⅱ型内漏分为两组(A组73例无内漏,B组50例有内漏)。30天死亡率A组22% vs B组16%(P=0.16),无显著差异;T2EL与30天死亡率无独立关联(OR 1.712,95%CI 0.591-3.964,P=0.54)。5年生存率A组53% vs B组59%(log-rank P=0.31),无显著差异;T2EL与长期死亡风险无独立关联(HR 1.068,95%CI 0.437-2.611,P=0.079)。
要点
- 30天死亡率A组22% vs B组16%(P=0.16),T2EL与30天死亡率无独立关联(OR 1.712,95%CI 0.591-3.964)。
- 5年生存率A组53% vs B组59%(log-rank P=0.31),T2EL与长期死亡风险无独立关联(HR 1.068,95%CI 0.437-2.611)。
核心结论
- T2EL在rAAA EVAR术后似乎相对常见,但其出现似乎不伴随围手术期更差结局,也不降低长期生存。
- 作者认为早期可谨慎观察,仅在持续血流动力学失代偿时选择性治疗;长期而言,存在T2EL时似乎可推荐与标准EVAR相同的治疗指征。
研究设计与样本
- 国际多中心研究,纳入德国、意大利和瑞士三家三级转诊中心2018年1月至2022年12月因rAAA行EVAR的全部患者。
- 共123例患者纳入最终分析,按有无早期T2EL(完成造影或首次术后CTA)分为A组无内漏73例和B组有内漏50例。
- 主要终点为30天死亡率和长期生存。
主要发现
- 基线除A组男性比例显著低于B组(79.5% vs 92%;P=0.05)外,无显著差异。
- 30天总死亡率A组22% vs B组16%(P=0.16),无显著差异;二元回归显示T2EL与30天死亡率无独立关联(OR 1.712,95%CI 0.591-3.964;P=0.54)。
- 5年生存率A组53% vs B组59%(log-rank P=0.31),无显著差异;Cox回归显示T2EL与长期死亡风险无独立关联(HR 1.068,95%CI 0.437-2.611;P=0.079)。
关键数值与推荐
- 早期T2EL定义:完成造影或首次术后CTA发现Ⅱ型内漏。
- 30天死亡率A组22% vs B组16%(P=0.16)。
- T2EL与30天死亡率OR 1.712(95%CI 0.591-3.964;P=0.54)。
- 5年生存率A组53% vs B组59%(log-rank P=0.31)。
- T2EL与长期死亡风险HR 1.068(95%CI 0.437-2.611;P=0.079)。
临床怎么用
- 作者认为早期可谨慎观察,仅在持续血流动力学失代偿时选择性治疗。
- 作者认为长期存在T2EL时,似乎可推荐与标准EVAR相同的治疗指征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ruptured abdominal aortic aneurysms (rAAAs) remain as a great clinical challenge for vascular surgeons and endovascular aortic repair (EVAR), which is currently regarded as the first-line treatment for rAAA in patients with appropriate anatomy. While recommendations for management of type II endoleaks (T2ELs) are well-established in the elective setting, data after rAAAs are limited. METHODS: Between January 2018 and December 2022, all patients who were treated with EVAR for rAAA in three tertiary referral centers from different countries (Germany, Italy, and Switzerland) were screened for inclusion in the study. The patients were divided into two groups based on the presence or absence of early T2EL (at completion angiography or at first postoperative computed tomography angiography). The primary end points for this study were 30-day mortality and long-term survival. RESULTS: Overall, 123 patients were included in the final analysis. Of these, 73 were categorized as not having an early T2EL (group A) and 50 presented an early T2EL (group B). Except for a significantly lower proportion of males in group A as compared with group B (79.5% vs 92%; P = .05), no significant baseline differences were found. At 30 days, the overall mortality rate was not significantly different between study groups (22% vs 16%; P = .16). Using binary regression, the presence of a T2EL was not associated independently with 30-day mortality (odds ratio, 1.712; 95% confidence interval, 0.591-3.964; P = .54). Five-year survival estimates in the whole study cohort did not show any significant difference in patients without a T2EL as compared to those with a T2EL (53% vs 59%; log-rank P = .31). Using Cox proportional hazard regression, the presence of T2ELs was not independently associated with increased risk for long-term mortality (hazard ratio. 1.068; 95% confidence interval, 0.437-2.611; P = .079). CONCLUSIONS: Although the occurrence of a T2EL seems to be a relatively common scenario after EVAR for rAAA, their presence does not seem to be associated with worse outcomes in the immediate perioperative period or to decrease long-term survival. Therefore, careful observation may be warranted in the early phase, with selective treatment only in cases of ongoing hemodynamic decompensation. In the long run, it seems prudent to assume that the same indication for treatment as for standard EVAR could be recommended in the presence of T2EL.
引用
- D'Oria M, Grando B, Menges AL, et al. International multicenter experience on early and late outcomes after endovascular repair of ruptured abdominal aortic aneurysms in patients with vs without type II endoleaks. J Vasc Surg. 2025. PMID: 40316187. doi:10.1016/j.jvs.2025.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。